Eli Lilly gets European OK for imaging agent Amyvid

01/15/2013 | Reuters

Eli Lilly & Co. has received approval from European regulators for its Alzheimer's disease PET imaging agent Amyvid. The move allows the use of the agent in adults with cognitive impairment who are being assessed for Alzheimer's and related conditions. The agent should be available in Europe in the second quarter of the year.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX